Psychiatric Medications
Ibogaine and benzodiazepines
Xanax, Klonopin, Valium, Ativan. Benzodiazepine dependence is not an indication for ibogaine, and no study says otherwise. But unlike almost every other psychiatric medication, you do not need to be off them before you arrive, and that changes what is possible.
How ibogaine can help, honestly told
Straight answer first: no trial has tested ibogaine for benzodiazepine dependence, and this page will not invent one. What we can tell you is how it actually goes on our campus, because people arrive with a benzodiazepine in their luggage more often than almost any other prescription.
The decision of what to do about it is made case by case, in screening, with the independent licensed Brazilian physicians who oversee every treatment. Some people keep their prescription. Many, once they are here, decide they want out. Both are respected.
The spiritual work: finding the eye of the storm
A benzodiazepine is a wall against overwhelm. The trouble is that the wall does not distinguish: it flattens panic and joy alike, and the anxiety usually learns to climb it anyway. The treatment experience runs the other direction. It is often demanding, sometimes harrowing,¹¹⁵ and inside it people report confronting exactly what they had been medicating away, followed by an unmistakable release.¹¹³ Our whole program is an education in that skill: not escaping the storm, but finding the still point inside it.
No pre-arrival taper, and why that matters
Benzodiazepines are not on the list of medications that must be out of your system before ibogaine the way QT-prolonging drugs are, and stopping them abruptly on your own is genuinely dangerous, so we never ask you to. What we have found is that many people choose to taper here: slowly, gradually, with physicians guiding the schedule and herbal support along the way. The environment does what willpower at home could not. The support system carries you through the nights the withdrawal would otherwise own.
Ibogaine is the first step, never the whole answer
A quarter of people in one study struggled to integrate an ibogaine experience without structure around it.¹²⁴ For benzodiazepines this matters double, because the taper itself takes time. That is why this is a program and a place, not a procedure: a strong, healthy environment with a spiritual, indigenous and philosophical approach to the mind is, in our experience, the only route to success that lasts.
Then, the neurochemistry, with a caveat
We will not oversell the biology. Ibogaine is not a GABA drug, and the evidence suggests it does not act on the benzodiazepine system directly. What it appears to offer is upstream: a sustained rise in the growth factor GDNF ⁸¹ and a broad recalibration of the systems that anxiety runs on.¹¹¹ Proposed mechanisms, honestly labeled as such. The taper is what gets you off the benzodiazepine. The treatment, and the month around it, is what changes your relationship with the fear.
The one medication you do not taper first
Every other page in this section asks you to complete a physician-guided taper before treatment. This one does not, because with benzodiazepines the dangerous move is the abrupt stop, not the continued use. The FDA itself states that physical dependence can develop within days to weeks, even taken exactly as prescribed,¹³³ and unsupervised withdrawal can be a medical emergency.
So the plan is made in screening, case by case. Some people go through treatment on their prescribed dose and decide about the medication later. Many choose a slow taper here on campus, with the schedule set by physicians and the days filled with something better than white-knuckling.
One thing is non-negotiable: full disclosure. Tell us everything you take. Screening decisions are only as good as the information they are built on.
Never stop a benzodiazepine abruptly, and never taper without medical guidance. Nothing on this page is medical advice; every plan is made with the independent licensed Brazilian physicians who screen and oversee treatment.
What carries you through a taper
A benzodiazepine taper at home fails for a predictable reason: the life that made the prescription necessary is still running at full volume around you. Here, the volume is off, and every day hands your nervous system a reason to trust itself again.
Exercise
Daily movement burns the adrenaline that a tapering nervous system produces in surplus. It is the most reliable tool we have, and we use it every single day.
Meditation
The core skill of the program: sitting inside discomfort without reaching for anything. Taught daily, because it is the thing the medication was doing for you.
The jungle
Atlantic rainforest on every side. It is very hard to sustain a panic loop next to a river that has been running for ten thousand years.
Daily walking and hiking
Trails from the front door, walked every day. Tired legs quiet a loud mind better than most molecules.
Excellent food
Cooked on site and eaten together. Blood sugar chaos mimics anxiety; we remove that variable at the table, three times a day.
Media detox
The news cycle and the feed are anxiety machines. They stay off for the month, and most people say the silence was half the cure.
And where the taper needs support, plants before prescriptions
When the nights get long, we reach for the plant traditions rather than another prescription: mulungu and saffron from South American practice, ashwagandha and brahmi from Ayurveda, chosen case by case with the medical team. A supportive, traditional role, never a substitute for the physician-guided schedule.
See the place the taper happens
The difference between a failed taper and a finished one is mostly environment. Come look at ours: the rooms, the river, the view you will be watching while your nervous system finds its feet.
The quietest dependency there is
Benzodiazepine dependence does not look like dependence. It lives in bathroom cabinets and handbags, prescribed, renewed and rarely questioned. Half of the people dispensed these drugs in the US take them beyond the two-month mark,¹³³ and among older adults, nearly one in three users is a long-term user, in the age group where the falls and fog hit hardest.
The guidance and the reality have quietly separated. The UK tells its doctors two to four weeks maximum.¹³⁵ The US dispenses ninety-two million prescriptions a year.¹³³ Somewhere between those two numbers are millions of people who were never told the wall they were given would become a cage.
We are not anti-medication. A benzodiazepine in a crisis is a mercy. A benzodiazepine as a decade-long default, with no plan and no exit, is a failure of imagination, and the people living inside it deserve better than a refill.
You were told that taking a medication would keep you calm. Instead, you most likely feel dull, and the anxiety still breaks through.
Our whole program is an education in how to embrace the overwhelm and the discomfort, until you find yourself in the eye of the storm.
Charles D. Johnston, Co-Founder, Nekawa
Calm that belongs to you
The promise of the benzodiazepine era was calm on demand. The cost, for many, was calm that never belonged to them: rented nightly, dulling more than it protected, harder to leave every year. We think the alternative is not a better molecule. It is a person retrained to stand inside their own weather.
That training is what the 28-Day UNprogram is for. Ibogaine, where the physicians approve it, is the beginning: a hard reset and, for many, the first unguarded look at the fear in years. The weeks after are the actual education: meditation, movement, the forest, the plant traditions, and a philosophy of mind drawn from indigenous practice that never confused sedation with peace.
If you are reading this with a prescription bottle within reach, hear the honest version: we cannot promise you an easy exit. We can promise a real plan, real physicians, and a month in a place where the exit has been walked before.
Citations (10)
[81] He DY, Ron D (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of ibogaine. The FASEB Journal, 20(13), 2420–2422. Read the source →
Shows ibogaine triggers a sustained, self-sustaining upregulation of GDNF in reward-related brain regions — a mechanism for effects that outlast the drug itself.
[111] Mash DC (2023). IUPHAR invited review — Ibogaine: A legacy within the current renaissance of psychedelic therapy. Pharmacological Research, 190, 106620. Read the source →
Mechanism synthesis: ibogaine inhibits the serotonin transporter noncompetitively, its long-lived metabolite noribogaine slows serotonin reuptake and acts as a G-protein-biased kappa-opioid agonist, and rapid antidepressant-like effects are thought to involve ketamine-like NMDA receptor blockade. All framed as proposed mechanisms under investigation, not demonstrated clinical effects.
[113] Heink A, Katsikas S, Lange-Altman T (2017). Examination of the phenomenology of the ibogaine treatment experience: role of altered states of consciousness and psychedelic experiences. Journal of Psychoactive Drugs, 49(3), 201–208. Read the source →
Survey of 27 people who underwent ibogaine treatment: all reported insights about their personal past, 97% experienced visions, 77% saw content drawn from their own childhood, and 85% reported subjective relief from guilt. Large majorities reported insights about the meaning of life, death, and creation. A small, self-selected online survey, reported as phenomenology rather than outcome evidence.
[115] Camlin TJ, Eulert D, Horvath AT, Bucky SF, Barsuglia J, Polanco M (2018). A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders. Journal of Psychedelic Studies, 2(1), 24–35. Read the source →
Qualitative study of 10 people treated with ibogaine in Mexico: 80% described the experience as physically draining, one comparing it to having survived cancer. The source for stating honestly that the treatment night is often demanding or harrowing rather than pleasant, which also helps explain ibogaine's low abuse potential.
[124] Davis AK, Renn E, Windham-Herman AM, Polanco M, Barsuglia JP (2018). A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification. Journal of Psychoactive Drugs, 50(4), 287–297. Read the source →
In a retrospective study of 73 people treated with ibogaine for opioid use disorder, roughly 23% reported difficulty integrating the experience into daily life afterwards. The evidence that ibogaine is a beginning that needs a structured program around it, not a standalone treatment.
[132] Maust DT, Lin LA, Blow FC (2019). Benzodiazepine use and misuse among adults in the United States. Psychiatric Services, 70(2), 97–106. Read the source →
30.6 million US adults, 12.6%, reported benzodiazepine use in the past year (2015–2016): 10.4% as prescribed and 2.2% misuse. Roughly double what prescription records alone had suggested. Self-report survey data.
[133] US Food and Drug Administration (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. FDA Drug Safety Communication, 23 September 2020. Read the source →
An estimated 92 million benzodiazepine prescriptions were dispensed from US pharmacies in 2019. About half of patients dispensed oral benzodiazepines received them for two months or longer, and the FDA states that physical dependence can develop within days to weeks of steady use, even when taken exactly as prescribed.
[134] National Institute on Drug Abuse (2025). Drug overdose deaths: facts and figures. National Institutes of Health (CDC WONDER mortality data). Read the source →
In 2023, 10,870 US overdose deaths involved benzodiazepines. The overwhelming majority also involved opioids, most recently illicit fentanyl; deaths from benzodiazepines alone are rare. "Involved" means the drug appeared on the death certificate, not that it was the sole cause.
[135] National Institute for Health and Care Excellence (2004). Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77). NICE Technology Appraisal Guidance 77. Read the source →
UK national guidance restricts hypnotic sleep medications, both z-drugs and benzodiazepine hypnotics, to short-term use only, generally no more than two to four weeks at the lowest effective dose, because tolerance and dependence can develop within weeks. Still-current guidance; millions take these drugs far longer.
[136] Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR (2023). Long-term consequences of benzodiazepine-induced neurological dysfunction: a survey. PLOS ONE, 18(6), e0285584. Read the source →
In the largest survey of benzodiazepine users to date (1,207 people recruited from support communities), a majority of those reporting symptoms such as anxiety, memory problems and low energy said they lasted a year or more after stopping. A self-selected sample: it documents that protracted withdrawal is real for some people, not how common it is. No reliable population prevalence exists.
Let’s connect.
No pressure. Tell us a little about what you’re going through.